

b.) IN THE ABSTRACT

Please amend the abstract at page 60 to read as follows.

Abstract of the Disclosure

~~The present invention relates to a compound~~ E2F-inhibiting compounds are  
represented by the general formula (I):  $R^1-A-R^2$  ~~{(I) (wherein  $R^1$  represents substituted or~~  
~~unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted~~  
~~heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or~~  
~~unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a~~  
~~hydrogen atom;  $R^2$  represents hydroxy, substituted or unsubstituted alkoxy, or substituted~~  
~~or unsubstituted amino; and~~ wherein A represents a peptide sequence comprising a partial  
amino acid sequence having at least 12 continuous residues in the sequence of the  
dimerization region or DNA binding region of the E2F family); ~~or a pharmaceutically~~  
~~acceptable salt thereof, which are useful as a therapeutic agent of diseases such as tumor~~  
and arteriosclerosis, for which abnormal cellular growth is responsible.